Development of the radioresistance conquest reinforcement therapy by an EGFR/FGFR dual inhibitor.
| Project/Area Number |
23659937
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
UZAWA Katsuhiro 千葉大学, 大学院・医学研究院, 准教授 (30302558)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KOUZU Yukinao 千葉大学, 大学院・医学研究院, 助教 (70400942)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 口腔癌 / 放射線治療 / EGFR / FGFR / デュアルインヒビター / PD173074 / FGFR3 / GFR |
|---|
| Research Abstract |
Conventional therapies including radiation therapy cannot cure squamous cell carcinoma and new treatments are clearly required. We identified the radiation resistance related gene (EGFR and FGFR) in the oral cancer cell line to overcome radiotherapy resistance for squamous cell carcinoma. In vivo, irradiation with dual inhibitor (PD173074) of EGFR and FGFR showed effective tumor suppression. Therefore it is considered to be very meaningful for the development of the radiation-enhancing treatment.
|
Report
(3 results)
Research Products
(2 results)
-
[Journal Article] Targeting fibroblast growth factor receptor 3 enhances radiosensitivity in human squamous cancer cells.2011
Author(s)
Uzawa K, Ishigami T, Fushimi K, Kawata T, Shinozuka K, Kasamatsu A, Sakamoto Y, Ogawara K, Shiiba M, Bukawa H, Ito H, Tanzawa H.
-
Journal Title
Oncogene.
Volume: 27;30(43)
Pages: 4447-52
Related Report
Peer Reviewed
-
